Abstract
Alzheimer’s disease (AD) impairs mental development and interrupts neurocognitive functions that escalate with time leading to death. With continuous evolution in lifestyle and progression of age, the prevalence of AD is progressively rising, leading to a significant economic burden. Thus, effective therapeutic approaches are indeed necessary to address this growing concern. Current treatment regimens primarily help to relieve the symptoms, nevertheless, with nanotechnology-based approaches the nerve damage can be regressed along with a reduction in inflammation and improved brain delivery. Researchers and healthcare professionals are working diligently to develop innovative treatments and interventions to improve the quality of life for individuals affected by AD. This review paper aims to provide comprehensive insights on disease pathogenesis, FDA-approved treatment, recent advancements in drug therapy, and innovative formulation approaches along with an update on drugs in different clinical phases. The review specifically highlights nanocrystals-based formulations and their ability to minimize side effects, improve drug bioavailability, pharmacodynamics and pharmacokinetics. The current review also prospects of role of NCs in enabling drug delivery across BBB and it dives deep to understand its potential to carve out directions in this niche area of treating AD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
